Emerging research suggests that tumor development involves much more than mutant clones.
A panel at the 2016 San Antonio Breast Cancer Symposium discussed the state of research and treatment of triple negative breast cancer (TNBC).
Many agents are in ongoing trials, and may provide additional options for patients with metastatic HER2-positive disease.
Lack of research data and failure to consider patients' functional age affects how older adults with breast cancer are managed.
Differences between the sexes are known in a variety of cancers, but the reasons remain unclear.
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Nivolumab + Ibrutinib Active in Relapsed/Refractory CLL and Richter Transformation
- The Challenges of Treating Triple-negative Breast Cancer
- Study Identifies Ultra-high Risk Category of Patients With DLBCL
- Oncoviruses and Epigenetic Factors May Contribute to Risk of Developing Lung Cancer
- The Current State of HER2+ Breast Cancer Management
- Non-Hodgkin Lymphoma (NHL) Treatment Regimens: Diffuse Large B-Cell Lymphoma
- Head and Neck Cancers Treatment Regimens
- Renal Cell Carcinoma Treatment Regimens
- Esophageal and Esophagogastric Junction Cancer Treatment Regimens
- Model Predicts That Healthful Lifestyle Benefits Women at Risk of Breast Cancer
- Circulating Tumor microRNA as Predictive Biomarkers in HER2+ Breast Cancer
- Complications of Post-mastectomy Irradiation
- CRISPR-Cas9 Mouse Xenograft Study Shows ESR1 Mutations Facilitate Metastasis
- Circulating Tumor Cells and Neoadjuvant Chemotherapy Outcomes
- Aromatase Inhibitors in HR+, HER2+ Breast Cancer